

Predicting Conversion from Self-Monitoring of Blood Glucose to Continuous Glucose Monitoring using clinical and demographic characteristics

Project committee:

Dr. Ebrahim Tarshizi
Capstone Instructor

Dr. Tyler Smith
University Advisor
National University

Mr. Hunter Aune
Industry Advisor



Team members:

Kornkanok Somkul

Peter Cao

Shashi Bala Lnu

MS in Data Science
School of Engineering
and Computing

May 21st, 2019


Our objective is to obtain insightful and actionable information to shape the diabetic industry



Location



Referrals




Age



Health insurance



Gender



Confounders




Finger-prick method

Analysis of factors



CGM method

Our objective is to obtain insightful and actionable information to shape the diabetic industry



In the last few decades, there have been significant technological leaps in glucose monitoring

SMBG



Urine testing, 1945 - 1957



The first test strip and meter, 1964-1970



Now

CGM



The first CGM, 2006



The first CGM mobile system, 2015



Now

FGM

The first FGM product, 2014



There are pros and cons for each current method of glucose monitoring

Self-monitoring blood glucose (SMBG)



Advantages

- Full glucose profile
- Alarms for “hypo”
- IP connection

Limitations

- High cost
- Need for calibration
- Difficulties in data interpretation

Flash glucose monitoring(FGM)



Advantages

- Full glucose profile
- No calibration
- Long sensor use
- Relatively affordable

Limitations

- No alarm for “hypo”
- No IP connection



Continuous glucose monitoring(CGM)


Advantages

- Familiarity
- Accuracy
- Relatively low cost



Limitations

- Inconvenience
- Pain/antisocial
- Sporadic nature

Majority of suggests that the CGM is superior to SMBG in many ways




Source: Burge, Mitchell, Sawyer, & Schade (2008)




Source: Chamberlain, Dopita, Gilgen, & Neuman (2015)


There are a few crucial factors for the likelihood of adopting a CGM device




Definite or likely adoption ~90%




The scope of our methodology is outlined in 8 steps




Data was gathered from diabetic patients across the U.S. and will be generated for the analyses in our project




These are the essential tools and techniques we will use to analyze the factors of glucose monitoring conversion



Incomplete, noisy, and inconsistent data will be changed into quality data, which can lead to significant improvement in the model's predictive performance





insurance_2	Frequency	Percent	Cumulative Frequency	Cumulative Percent
GOVERNMENT INS	25235	51.64	25235	51.64
COMMERCIAL INS	23490	48.07	48725	99.71
N/A	141	0.29	48866	100.00




Incomplete, noisy, and inconsistent data will be changed into quality data, which can lead to significant improvement in the model's predictive performance



Strip brands (12 levels)



Strip brands (7 levels)



There should be minimal or no multicollinearity among the independent variables. A variance inflation factor (VIF) value of more than 4 is an alarming value that the variables may be confounding.



Chi-square analyses were performed to determine bivariate associations between categorical variables


Bivariate Associations of Demographic and Clinical Characteristics of 47,968 Diabetic Patients from ADS by Referrals

Variable	Population N = 47,968 ^a (100%)	Agent N=13,772 (28.71%)	Commercial N=23,312 (48.60%)	Healthcare administration N=10,884 (22.69%)	p-value ^b
<u>Gender</u>					
Female	26,620 (55.5%)	8,520 (61.9%)	12,136 (52.1%)	5,964 (54.8%)	<0.0001
Male	21,348 (44.5%)	5,252 (38.5%)	11,176 (48.0%)	4,920 (45.2%)	
<u>Medicare jurisdiction</u>					
Jurisdiction A	4,921 (10.2%)	685 (5.0%)	3,708 (15.9%)	528 (4.8%)	<0.0001
Jurisdiction B	5,202 (10.9%)	1,825 (13.2%)	2,881 (12.4%)	496 (4.6%)	
Jurisdiction C	19,668 (41.0%)	9,960 (72.3%)	7,996 (34.3%)	1,712 (15.7%)	
Jurisdiction D	18,177 (37.9%)	1,302 (9.4%)	8,727 (37.4%)	8,148 (74.9%)	
<u>Age</u>					
Children and young adult (1-26)	4,197 (8.7%)	7 (0.1%)	4,123 (17.7%)	67 (0.6%)	<0.0001
Adult (27-64)	11,867 (24.7%)	3,528 (25.6%)	6,370 (27.3%)	1,969 (18.1%)	
Senior (65+)	31,904 (66.5%)	10,237 (74.3%)	12,819 (55.0%)	8,848 (81.3%)	
<u>Diabetes type</u>					
T1D	11,237 (23.4%)	536 (3.9%)	10,128 (43.5%)	573 (5.3%)	<0.0001
T2D	36,731 (76.6%)	13,236 (96.1%)	13,184 (56.5%)	10,311 (94.7%)	
<u>Eligibility waiver</u>					
Not on waiver	42,074 (87.7%)	10,370 (75.3%)	21,456 (92.0%)	10,248 (94.2%)	<0.0001
On waiver	5,894 (12.3%)	3,402 (24.7%)	1,856 (8.0%)	636 (5.8%)	
<u>Patient reorder opportunity offer</u>					
Compliant	34,420 (71.8%)	9,749 (70.8%)	17,035 (73.1%)	7,636 (70.2%)	<0.0001
Non-compliant	13,548 (28.2%)	4,023 (29.2%)	6,277 (26.9%)	3,248 (29.8%)	
<u>Insurance</u>					
Commercial	23166 (48.3%)	9,671 (70.2%)	9,303 (39.9%)	4,192 (38.5%)	<0.0001
Government	24802 (51.7%)	4,101 (29.8%)	14,009 (60.1%)	6,692 (61.5%)	

Bivariate Associations of Demographic and Clinical Characteristics of 47,968 Diabetic Patients from ADS by CGM Conversion

Variable	Population N = 47,968* (100%)	Not convert N = 42,599 (88.81%)	Converted N = 5,369 (11.19%)	p-value ^b
<u>Referral type</u>				
Agent	13,772 (28.7%)	13,709 (32.2%)	63 (1.2%)	<0.0001
Commercial	23,312 (48.6%)	18,742 (44.0%)	4,570 (85.1%)	
HCA	10,884 (22.7%)	10,148 (23.8%)	736 (13.7%)	
<u>Gender</u>				
Female	26,620 (55.5%)	23,936 (56.2%)	2,684 (50.0%)	<0.0001
Male	21,348 (44.5%)	18,663 (43.8%)	2,685 (50.0%)	
<u>Medicare jurisdiction</u>				
Jurisdiction A	4,921 (10.3%)	3,904 (9.2%)	1,017 (18.9%)	<0.0001
Jurisdiction B	5,202 (10.8%)	4,250 (10.0%)	952 (17.7%)	
Jurisdiction C	19,668 (41.0%)	18,379 (43.1%)	1,289 (24.0%)	
Jurisdiction D	18,177 (37.9%)	16,066 (37.7%)	2,111 (39.3%)	
<u>Age</u>				
Child and young adult (1-26)	4,197 (8.8%)	4,187 (9.8%)	10 (0.2%)	<0.0001
Adult (27-64)	11,867 (24.7%)	10,772 (25.3%)	1,095 (20.4%)	
Senior (65+)	31,904 (66.5%)	27,640 (64.9%)	4,264 (79.4%)	
<u>Diabetes type</u>				
T1D	11,237 (23.4%)	10,093 (23.7%)	1,144 (21.3%)	<0.0001
T2D	36,731 (76.6%)	32,506 (76.3%)	4,225 (78.7%)	
<u>Eligibility waiver</u>				
Not on waiver	42,074 (87.7%)	37,253 (87.5%)	4,821 (89.8%)	<0.0001
On waiver	5,894 (12.3%)	5,346 (12.5%)	548 (10.2%)	
<u>Patient reorder opportunity offer</u>				
Compliant	34,420 (71.8%)	30,130 (70.7%)	4,290 (79.9%)	<0.0001
Non-compliant	13,548 (28.2%)	12,469 (29.3%)	1,079 (20.1%)	
<u>Insurance</u>				
Commercial	23,166 (48.3%)	22,661 (53.2%)	505 (9.4%)	<0.0001
Government	24,802 (51.7%)	19,938 (46.8%)	4,864 (90.6%)	

Chi-square analyses were performed to determine if there is an association between the variable of interest (referrals) and each control variable




Statistics for Table of insurance_2 by referral_type2

Statistic	DF	Value	Prob
Chi-Square	4	3741.2786	<.0001



There is an association between referrals (VOI) and insurance type

Chi-square analysis was performed to determine if there is an association between the dependent variable (CGM conversion) and referrals



Statistics for Table of referral_type2 by CGM_Conversion			
Statistic	DF	Value	Prob
Chi-Square	4	4406.9150	<.0001




There is an association between converting patients (DV) and referrals

The train/test data split operation was done in the ratio of 3:1 to validate our results properly

% split		75%	25%	
		Train set	Test set	
		Frequency (%)	Frequency (%)	Total
Non-event		32,568 (89%)	10,856 (89%)	43,424
Event		1,360 (11%)	4,082 (11%)	5,442
Total event		35,481	11,826	<u>48,866</u>


Multiple multivariate analyses account for other variables at the same time, and can be utilized for predictive modeling

Linear discriminant analysis




Source: Thatcher T. (2015)

Logistic regression




Source: (Banga, 2016)


Decision tree



Random forest




Gradient boosting



Logistic regression

Odds Ratios with 95% Wald Confidence Limits



Association of Predicted Probabilities and Observed Responses

Percent Concordant	84.6	Somers' D	0.701
Percent Discordant	14.5	Gamma	0.707
Percent Tied	0.9	Tau-a	0.139
Pairs	128662650	c	0.850


Partition for the Hosmer and Lemeshow Test

Group	Total	CGM_Conversion = 1		CGM_Conversion = 0	
		Observed	Expected	Observed	Expected
1	1225	2	0.98	1223	1224.02
2	1049	3	1.52	1046	1047.48
3	1182	2	3.02	1180	1178.98
4	1303	17	14.82	1286	1288.18
5	1322	36	40.97	1286	1281.03
6	1339	96	100.75	1243	1238.25
7	1181	120	130.82	1061	1050.18
8	1340	350	326.31	990	1013.69
9	1331	409	404.44	922	926.56
10	719	306	317.37	413	401.63

Hosmer and Lemeshow Goodness-of-Fit Test

Chi-Square	DF	Pr > ChiSq
8.1120	8	0.4226

ROC Curves for Comparisons




Odds Ratio Estimates and Wald Confidence Intervals

Effect	Unit	Estimate	95% Confidence Limits	
referral_type2 COMMERCIAL vs AGENT	1.0000	40.347	24.437	66.616
referral_type2 HCA vs AGENT	1.0000	12.751	7.561	21.505
gender male vs female	1.0000	1.215	1.071	1.378
MEDIJURI A vs D	1.0000	1.846	1.545	2.206
MEDIJURI B vs D	1.0000	2.534	2.088	3.075
MEDIJURI C vs D	1.0000	1.169	0.989	1.382
age_cat 1 vs 3	1.0000	0.008	0.001	0.056
age_cat 2 vs 3	1.0000	0.988	0.838	1.165
insurance_2 COMMERCIAL INS vs GOVERNMENT INS	1.0000	0.156	0.127	0.192

Analysis of Maximum Likelihood Estimates

Parameter		DF	Estimate	Standard Error	Wald Chi-Square	Pr > ChiSq	Standardized Estimate
Intercept		1	-4.8684	0.2622	344.7628	<.0001	
referral_type2	COMMERCIAL	1	3.6975	0.2558	208.8608	<.0001	1.0185
referral_type2	HCA	1	2.5456	0.2687	91.1230	<.0001	0.9918
gender	male	1	0.1946	0.3643	9.1496	0.0025	0.0533
MEDIJURI	A	1	0.6130	0.3908	45.5474	<.0001	0.1040
MEDIJURI	B	1	0.9297	0.3997	88.8579	<.0001	0.1821
MEDIJURI	C	1	0.1559	0.3853	3.3382	0.0677	0.0422
age_cat	1	1	-4.8391	1.0017	23.3361	<.0001	-0.7466
age_cat	2	1	-0.0120	0.3839	0.0206	0.8859	-0.00287
insurance_2	COMMERCIAL INS	1	-1.8577	0.1057	309.0088	<.0001	-0.5120

The referral variable did indeed have the highest impact in both the unadjusted and adjusted analyses




Commercial(10): ADS Marketing, ADS employee, Insurance company, DEXCOM, trade show, DME, gas card referral, manufacturer, internet, patient referral

Agents(5): UHC Agent, ICA Agent, EDC Agent, managed care broker, insurance broker

Other(3): miscellaneous, unknown, acquisition

Healthcare administrations(17): Home health, hospital, pharmacy, pharmacy partner, blind center, managed care, LTC, assisted living, CA Medical groups, medical group, clinic, medicaid, medi-cal, endocrinologist, health professional, physician, CDE



As expected, none of the SMBG patients converted without being prompted; but when there were prompted, almost all of them converted!

93% Chance of conversion
after being prompted



Finger-prick method




CGM method

The multivariate analysis indicated that only five variables were viable for predicting CGM conversion: referral type, region, age, gender and health insurance



Referral type




Region



Health insurance




Gender



Age

Patients device type profile by state in United States



Other insights on clinical factors that had a significant impact on CGM conversion were people on eligibility waivers, if they were compliant, and their insurance



Not on eligibility waiver




Type II patients




Compliant patients


Diabetic type II patients are more likely to convert to CGM compared to diabetic type I patients



Patients have high probability to convert within three to four months after they become a member of ADS



T-tests for continuous variables revealed that patients on the CGM method regularly test more often than those on the SMBG method



CGM_Conversion	Method	Mean	95% CL Mean	Std Dev	95% CL Std Dev
0		2.1513	2.1375 2.1651	1.4414	1.4316 1.4512
1		4.3649	4.3319 4.3979	1.2384	1.2155 1.2622
Diff (1-2)	Pooled	-2.2136	-2.2538 -2.1734	1.4195	1.4105 1.4286
Diff (1-2)	Satterthwaite	-2.2136	-2.2494 -2.1778		



Finger-prick
method

==

Testing 2
times a day





CGM method

==

Testing 4
times a day

Current research suggests that socio-economic and emotional factors play large roles in conversion as well

1. Generalizability



2. Socio-economic factors



Educational attainment



Income level



Occupation

3. Emotional factors



Parental Control



Child ostracization



Adjusted to former SMBG

Future studies will need to be conducted on emotional/social variables, expansion and financial administration with insurance coverage



versus



Source: Inkwood research (2019)

Thank you for viewing our presentation!

References

- Medi-Cal reimbursing for advance care planning, uses same codes as Medicare. (2016, June 15). Retrieved April 23, 2019, from Coalition for Compassionate Care of California website: <https://coalitionccc.org/2016/06/medi-cal-reimburses-advance-care-planning/>
- Medicare Expansion Steps Into the Political Limelight. (2018, September 30). Retrieved April 23, 2019, from Managed Care magazine website: <https://www.managedcaremag.com/archives/2018/10/medicare-expansion-steps-political-limelight>
- McCrimmon, R. J., & Sherwin, R. S. (2010). Hypoglycemia in Type 1 Diabetes. *Diabetes*, 59(10), 2333–2339. <https://doi.org/10.2337/db10-0103>
- Weighing Options Bilder, arkivbilder og. Retrieved April 23, 2019, from <https://www.shutterstock.com/nb/search/weighing+options>
- 2b. ZestGluco “Silver” Strips & Lancets Pack - 100 each. (n.d.). Retrieved April 23, 2019, from ZestGluco website: <https://zestgluco.co.nz/products/3-zestgluco-silver-strips-lancets-pack-100-each>
- 2016-2017 Board of Governors Fee Waiver Program ELIGIBILITY REQUIREMENTS. (n.d.). Retrieved April 23, 2019, from studylib.net website: <https://studylib.net/doc/12982432/2016-2017-board-of-governors-fee-waiver-program-eligibili...>
- Types of health insurance plans. (2018, November 14). Retrieved April 23, 2019, from insurance website: <https://thefamilyhouse.org/types-of-health-insurance-plans/>
- Continuous Glucose Measuring Smartwatch, K’Watch Glucose, Expected Soon. (2018, November 28). Retrieved April 23, 2019, from Medgadget website: <https://www.medgadget.com/2018/11/continuous-glucose-measuring-smartwatch-kwatch-glucose-expected-soon.html>
- Type 2 Diabetes Not Linked To Weight Gain. (2014, February 11). Retrieved April 23, 2019, from Medical Daily website: <https://www.medicaldaily.com/type-2-diabetes-not-linked-weight-gain-onset-diabetes-happens-differently-depending-patient-269108>